[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364012-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364012-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","t-cell-receptor-repertoire-dynamics-and-newly-identified-functional-regulators-of-autologous-tumor-infiltrating-lymphocyte-therapy-in-advanced-solid-tumors-research-findings","T cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors - Research Findings","","Tumor-infiltrating lymphocyte (TIL) therapy shows clinical promise in melanoma, yet its effectiveness across diverse solid tumors in Asian patients remains unclear. A phase I investigator-initiated trial evaluated autologous TIL therapy in twelve advanced cancer patients, assessing safety, feasibility, early efficacy, and biomarker dynamics. Infused TIL persisted in blood with reversal of CD4+ to CD8+ ratios, while TCR clonal remodeling correlated with responders. Transcriptomic profiling linked ASS1 and CEP20 as negative regulators; CRISPR/Cas9 knockout enhanced memory phenotypes, cytokines, and tumor cytotoxicity. ",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/t-cell-receptor-repertoire-dynamics-and-newly-identified-functional-regulators-of-autologous-tumor-infiltrating-lymphocyte-therapy-in-advanced-solid-tumors-research-findings/364012/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/t-cell-receptor-repertoire-dynamics-and-newly-identified-functional-regulators-of-autologous-tumor-infiltrating-lymphocyte-therapy-in-advanced-solid-tumors-research-findings/364012.png","ImageObject",300,407,{"name":42,"@type":43},"OmBimo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the phase I trial?","Question",{"text":63,"@type":64},"To assess the safety, feasibility, and preliminary efficacy of autologous TIL therapy in patients with advanced solid tumors, while evaluating molecular and TCR repertoire dynamics tied to response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What response rates were observed in the study?",{"text":68,"@type":64},"The objective response rate (ORR) was 33.3% (4/12) with one complete response and three partial responses, and the disease control rate (DCR) was 75% (9/12).",{"name":70,"@type":61,"acceptedAnswer":71},"Which genes were identified as negative regulators of TIL efficacy and what did CRISPR knockout do?",{"text":72,"@type":64},"Transcriptomic profiling identified ASS1 and CEP20 as negatively associated with therapeutic efficacy; CRISPR/Cas9-mediated knockout enhanced TIL memory phenotypes, cytokine production, and tumor cytotoxicity in vitro and in vivo.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364012,1790216234,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Li et al. Journal of Translational Medicine (2026) 24:1068  \n[https://doi.org/10.1186/s12967-026-08781-z](https://doi.org/10.1186/s12967-026-08781-z)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nT cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors  \nFenge Li1,2†, Jilong Yang3†, Gregory Lizee4, Yongming Xue5, Ruijing Wang1, Chao Zhang3, Xinbo Gao6, Xiangqin Zhao6, Mei Liu1, Wenhan Lu5, Yupeng Wang2, Weihong Feng2, Chunhua Ma1* andYing Ma6*  \nAbstract  \nBackground Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated clinical potential in melanoma; however, its applicability across diverse solid tumors in Asian patients remains unclear. Identification of molecular targets to enhance the antitumor activity of TIL is urgently needed.  \nMaterials and methods In a phase I investigator-initiated trial, we evaluated the safety, feasibility, and preliminary efficacy of autologous TIL therapy in twelve patients with advanced melanoma, cervical, lung, or head and neck cancers. Twelve patients who had progressed after standard therapies were enrolled between August 2022 and December 2024. Patients received lymphodepletion with cyclophosphamide (30 mg/kg) for 2 days, followed by fludarabine (25 mg/m²) for 5 days, approximately 24 h before intravenous infusion of autologous TIL. High-dose interleukin-2 (IL-2) was administered for 6–12 days to support T-cell survival and expansion. After a 28-day safety observation period, tumor assessments were performed every 6 weeks for the first 6 months and thereafter every 12 weeks during long-term follow-up, according to RECIST 1.1 criteria. T cell receptor (TCR) sequencing was conducted to evaluate in vivo persistence of infused TIL. Differential gene expression analysis was performed using bulk RNA sequencing on TIL from responders and non-responders. Target gene knockout inTIL was achieved using CRISPR/ Cas9 technology to assess enhancement of antitumor function.  \nResults The most common adverse events were fever, anemia, nausea, hypertension, and hyponatremia. The objective response rate (ORR) was 33 . 3%(4/12), including one complete response (CR) and three partial responses (PR), with a disease control rate (DCR) of 75%(9/12) . Infused TIL persisted in peripheral blood and induced a reversal in the peripheral CD4 + T to CD8 + T cell ratio. TCR sequencing revealed dynamic clonal remodeling in responders. Transcriptomic profiling identified ASS1 and CEP20 as genes negatively associated with therapeutic efficacy. CRISPR/  \n†Fenge Li and Jilong Yang contributed equally to this work.  \n*Correspondence: Chunhua Ma[mch8178@163.com](mch8178@163.com)[ ](mch8178@163.com)Ying Ma  \n[yingma@tmu.edu.cn](yingma@tmu.edu.cn); [yingma_maying@hotmail.com](yingma_maying@hotmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-","cbCail3uP5WeFZg5","https://ap.wps.com/l/cbCail3uP5WeFZg5","pdf",3533771,23,"English","# Abstract\n## Background\n## Materials and methods\n## Results\n## Conclusions\n# Highlights\n# Significance","[{\"question\":\"What was the main goal of the phase I trial?\",\"answer\":\"To assess the safety, feasibility, and preliminary efficacy of autologous TIL therapy in patients with advanced solid tumors, while evaluating molecular and TCR repertoire dynamics tied to response.\"},{\"question\":\"What response rates were observed in the study?\",\"answer\":\"The objective response rate (ORR) was 33.3% (4/12) with one complete response and three partial responses, and the disease control rate (DCR) was 75% (9/12).\"},{\"question\":\"Which genes were identified as negative regulators of TIL efficacy and what did CRISPR knockout do?\",\"answer\":\"Transcriptomic profiling identified ASS1 and CEP20 as negatively associated with therapeutic efficacy; CRISPR/Cas9-mediated knockout enhanced TIL memory phenotypes, cytokine production, and tumor cytotoxicity in vitro and in vivo.\"}]","T cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors - Research Findings | PDF",1790155105,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9737f53a5a87abfbe912d55487846c0.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1055c02fbc95bc79104d06eae7e959da.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/264ae603a2c8528948a2505abf2efcb8.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d28e6bb0721d1e09e63a58d05e49e72.webp",980,1306]